Since the outbreak of the SARS-CoV-2 pandemic in 2019, our understanding of the disease and its pathophysiology has rapidly evolved, leading to more effective therapeutic and prophylactic approaches, including vaccination. As a result of the global vaccination campaign, mortality and hospitalization due to COVID-19 have been significantly reduced, especially in developed countries. However, the exact immune response to SARS-CoV-2 is still under debate and not all of the details are fully understood. SARS-CoV-2 is continuously mutating and poses a major challenge to cellular and humoral immunity, as well as vaccination. Therefore, a better understanding of the immunological background of the disease is of utmost importance in order to develop more effective prevention and treatment strategies.
The goal of this Research Topic is to present new data regarding the immune response to SARS-CoV-2 and its implication for the clinical outcome. Conflicting results have been published regarding the role of the ABO blood group system, prompting further investigation. In the context of the pandemic, it is very important to understand the sensitivity of T-cells among different population groups due to the differences in their HLA haplotypes. Characterization of the immune response among population groups can help design personalized therapies for patients with high disease severity. Also, new therapeutic approaches could be presented in this Research Topic.
This Research Topic welcomes Original Research and Review/Mini Review articles which focus on, but are not limited to, the following themes:
• The immunogenetic response to SARS-CoV-2
• The role of blood groups
• HLA response
• T-cell response
Original Research articles or meta-analysis are welcome. By drawing together the newest studies into this topic, we expect to gain deeper understandings into how the immune system components are working during a SARS-CoV-2 infection and what we can do to prevent the cytokine storm and its lethal outcome.
Since the outbreak of the SARS-CoV-2 pandemic in 2019, our understanding of the disease and its pathophysiology has rapidly evolved, leading to more effective therapeutic and prophylactic approaches, including vaccination. As a result of the global vaccination campaign, mortality and hospitalization due to COVID-19 have been significantly reduced, especially in developed countries. However, the exact immune response to SARS-CoV-2 is still under debate and not all of the details are fully understood. SARS-CoV-2 is continuously mutating and poses a major challenge to cellular and humoral immunity, as well as vaccination. Therefore, a better understanding of the immunological background of the disease is of utmost importance in order to develop more effective prevention and treatment strategies.
The goal of this Research Topic is to present new data regarding the immune response to SARS-CoV-2 and its implication for the clinical outcome. Conflicting results have been published regarding the role of the ABO blood group system, prompting further investigation. In the context of the pandemic, it is very important to understand the sensitivity of T-cells among different population groups due to the differences in their HLA haplotypes. Characterization of the immune response among population groups can help design personalized therapies for patients with high disease severity. Also, new therapeutic approaches could be presented in this Research Topic.
This Research Topic welcomes Original Research and Review/Mini Review articles which focus on, but are not limited to, the following themes:
• The immunogenetic response to SARS-CoV-2
• The role of blood groups
• HLA response
• T-cell response
Original Research articles or meta-analysis are welcome. By drawing together the newest studies into this topic, we expect to gain deeper understandings into how the immune system components are working during a SARS-CoV-2 infection and what we can do to prevent the cytokine storm and its lethal outcome.